Insightful analysis and commentary for the US and global equity investor
Contributors: Douglas McIntyre Jon C. Ogg

Previous Posts

Wednesday, July 12, 2006

Stem Cell Alert (Round 3)


Last week we alerted that there would likely be a vote on much broader stem cell funding in Congress and noted that delays were likely or possible. Sure enough, by the end of the week there was a delay. Now it looks like this may come next week, as reports are noting that Senate Majority Leader Bill Frist has indicated that the vote will be next week.

Remember, regardless of who is in power and who isn't, we are dealing with Congress and a myriad of minor to major issues could cause delays again. Stem cell companies still have to get passed the Bush threat to veto much of this, and this vote will not likely be proposed until the backers in Congress feel they have enough votes to overturn a veto.

The stocks that have historically had the most exposure to stem cell research backing are the following: Aastrom Bio (ASTM), Geron (GERN), StemCells (STEM), ViaCell (VIAC), Thermogenesis (KOOL) and Advanced Cell Technology Inc. (ACTC-OTC); Invitrogen (IVGN) has also been recently lumped in after a deal with Geron.

Jon C. Ogg
July 12, 2006

Powered by Blogger